Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

Bronchiectasis may affect anyone of any age, but most commonly the middle-aged segment. Unfortunately, the damage done to the lungs by bronchiectasis is permanent. The bronchi are small tubes in the ...

Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this incurable condition.

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

Glenview, Illinois – On World Bronchiectasis Day (July 1), the American College of Chest Physicians (CHEST) is announcing the launch of Bridging Specialties ®: Timely Diagnosis for NTM Disease and ...

Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on bronchiectasis. Bronchiectasis is an ...